Intrinsic and Extrinsic Challenges in Rare Diseases: Connecting Global Collaboration with National Health-System Realities

Rare diseases are conditions so uncommon that a single doctor might see only a handful of cases in an entire career. Yet, when you add up all the thousands of different rare conditions, they affect a significant portion of the global population, creating a massive, collective health challenge. The difficulty in treating these illnesses stems from two very different sources. The first source is the nature of the diseases themselves: because so few people have them, it is hard to gather enough patients to study, the biology is often complex and poorly understood, and there is little financial motivation for companies to develop new medicines. The second source is the environment where patients live: the quality of care, the availability of specialists, the rules for getting treatment, and the money to pay for it all depend entirely on which country a person calls home. While scientists have long known that sharing data across borders is essential to solve the biological puzzles, a new perspective suggests that sharing knowledge is not enough if the local health systems cannot deliver that knowledge to the people who need it.

Emilio J. A. Roldan, a scientific coordinator for a foundation dedicated to rare diseases, argues that we must stop treating all the challenges of rare diseases as if they were the same problem. In his analysis, he separates the issues into two distinct categories: intrinsic challenges and extrinsic challenges. The intrinsic challenges are the universal hurdles that exist no matter where a patient lives. These include the small number of people with a specific condition, the lack of known biological mechanisms, and the difficulty of running clinical trials when there are so few participants. Because these problems are shared by everyone, the solution is global cooperation. Scientists in different countries must share their data, use the same definitions for diseases, and work together to build the tools needed to understand these conditions. This is why international networks and shared databases are so vital; they allow the world to pool its limited resources to solve problems that no single nation could tackle alone.

However, Roldan points out that global science hits a wall when it meets the reality of local health systems. This is where the extrinsic challenges begin. These are the barriers created by the country or region where a patient lives. They include fragmented care where different doctors do not talk to each other, long delays in getting a diagnosis, a lack of specialists, and financial hurdles that prevent people from getting the tests or medicines they need. A child with a rare genetic condition might receive a quick diagnosis and life-saving treatment in one country, while a child with the exact same condition in a different country might wait years, never get a clear answer, and receive no treatment at all. The paper emphasizes that these differences are not just minor details; for many patients, the extrinsic environment determines whether their condition is even recognized, recorded, or treated.

The author suggests that many current global programs fail because they try to copy-paste solutions designed for wealthy nations into settings that lack the necessary infrastructure. A plan that works perfectly in a country with advanced hospitals and stable funding may collapse in a place where doctors are overworked, data systems are missing, and budgets are tight. Roldan argues that international collaboration should focus on solving the shared scientific problems, while each country must build its own national plan to handle the local delivery of care. This national plan needs to be realistic, taking into account the country's specific economic situation, its health system, and its social needs. It cannot simply be a copy of a plan from another continent; it must be a tailored strategy that turns global knowledge into local action.

A critical part of this national strategy is how we count and track patients. Currently, most official records only include people who have a confirmed diagnosis. Roldan argues that this approach leaves out a huge group of people: those who are sick with rare symptoms but have not yet received a definitive label, or those whose diagnosis is still a strong suspicion. If a country only counts confirmed cases, the problem looks smaller than it really is, and the people who need help the most remain invisible. To fix this, the paper proposes a "layered registry." This is a system that records not just confirmed cases, but also people with suspected rare diseases and those with unexplained, complex symptoms. This registry would act as a foundation for the national plan, helping leaders see the true scale of the need and directing resources to where they are most required, even before a final diagnosis is made.

The paper also addresses the situation in low- and middle-income countries, warning against the idea that these nations are merely places to recruit patients for studies done elsewhere. Instead, these countries possess their own scientific talent and unique populations that can contribute to global knowledge. The goal should be equitable partnerships where local researchers help set the agenda, share in the credit, and ensure that the benefits of research return to their communities. Roldan suggests that even countries with limited budgets can make progress by focusing on practical steps: improving how doctors recognize symptoms, creating clear rules for referring patients to specialists, and building simple systems to track cases. Small investments in organization and information can prevent wasted effort and make future investments more effective.

Ultimately, the paper concludes that solving the crisis of rare diseases requires a dual approach. We need global science to unlock the mysteries of these conditions, but we also need local responsibility to ensure that the solutions actually reach the patients. A successful global program should set high standards for cooperation while allowing each country the flexibility to adapt those standards to their own reality. The most important takeaway is that policy must extend beyond those who are lucky enough to have a confirmed diagnosis. People with suspected or undiagnosed rare conditions must be included in the plan, because their suffering is just as real, and their need for care is just as urgent. By distinguishing between the universal scientific hurdles and the local system barriers, we can connect the ambition of global research with the practical reality of daily life, ensuring that progress is not just a concept in a lab, but a tangible improvement for patients everywhere.